000			04468cam a2200481 i 4500
001			34419
003			MED
005			20250812113208.0
006			m o d
007			cr |n|---|||||
008			160111s2015 mou o 000 0 eng d
020			_a0128010762
020			_a9780128010761
035			_a(OCoLC)990756593
040			_aLIP _beng _cLIP _dOCLCQ _dESU _dOCLCQ _dOCLCL _dOCLCQ _dOCLCL
082	0	4	_a615/.19 _qOCoLC _222/eng/20230216
100	1		_aDi, Li.
245	1	0	_aDrug-Like Properties : _bConcepts, Structure Design and Methods from ADME to Toxicity Optimization.
246	3		_aDrug-Like Properties - Concepts, Structure, Design, and Methods from ADME to Toxicity Optimization
250			_a2nd ed.
260			_aSaint Louis : _bElsevier Science, _c2015.
300			_a1 online resource (582 pages)
336			_atext _btxt
337			_acomputer _bc
338			_aonline resource _bcr
500			_a7.1. Introduction.
505	0		_aFront Cover; Drug-Like Properties: Concepts, Structure, Design, and Methods from ADME to Toxicity Optimization; Copyright; Dedication; Contents; Preface; Preface to Second Edition; Preface to First Edition; Chapter 1: Introduction; 1.1. Drug-like Properties in Drug Discovery; 1.2. Purpose of This Book; Problems; References; Chapter 2: Benefits of Property Assessment and Good Drug-Like Properties; 2.1. Introduction; 2.2. Discovery Scientists Optimize Many Properties; 2.3. Introduction to the Drug Discovery and Development Process; 2.4. Benefits of Good Drug-like Properties.
505	8		_a2.4.1. Reduced Development Attrition2.4.2. More Efficient Drug Discovery; 2.4.3. More Efficient Drug Development; 2.4.4. Higher Patient Compliance; 2.4.5. Improved Biological Research in Drug Discovery; 2.4.6. Enabled Partnerships for Drug Development; 2.4.7. Human Modeling and Clinical Planning; 2.4.8. Balance of Properties and Activity; 2.5. Property Profiling in Drug Discovery; 2.6. Drug-like Property Optimization in Drug Discovery; Problems; References; Chapter 3: In Vivo Environments Affect Drug Exposure; 3.1. Introduction; 3.2. Drug Dosing; 3.3. Stomach.
505	8		_a3.3.1. Gastric Acidic Degradation3.4. Intestinal Environment; 3.4.1. Dissolution Rate; 3.4.2. Solubility; 3.4.3. Permeability; 3.4.4. Intestinal Metabolism; 3.4.5. Intestinal Enzymatic Hydrolysis; 3.4.6. Absorption Enhancement in the Intestine; 3.5. Bloodstream; 3.5.1. Plasma Enzyme Hydrolysis; 3.5.2. Plasma Protein Binding; 3.5.3. Red Blood Cell Binding; 3.6. Liver; 3.6.1. Permeation into and out of Hepatocytes; 3.6.2. Hepatic Metabolism; 3.6.3. Biliary Extraction; 3.7. Kidney; 3.8. Blood-Tissue Barriers; 3.9. Tissue Distribution; 3.9.1. Nonspecific Binding in Tissue.
505	8		_a3.10. Consequences of Chirality3.11. Overview of in vivo Challenges to Drug Exposure; Problems; References; Chapter 4: Prediction Rules for Rapid Property Profiling from Structure; 4.1. Introduction; 4.2. General Concepts for Prediction Rules; 4.3. Rule of 5; 4.4. Veber Rules; 4.5. Waring Rules; 4.6. Golden Triangle; 4.7. Other Predictive Rules; 4.8. Application of Rules for Compound Assessment; 4.9. Applications of Predictive Rules; Problems; References; Chapter 5: Lipophilicity; 5.1. Lipophilicity Fundamentals; 5.2. Lipophilicity Effects.
505	8		_a5.3. Lipophilicity Case Studies and Structure Modification5.3.1. Lipophilicity Modification for Biological Activity; 5.3.2. Lipophilicity Modification for Pharmacokinetics; 5.3.3. Lipophilicity Modification for Toxicity; Problems; References; Chapter 6: pKa; 6.1. pKa Fundamentals; 6.2. pKa Effects; 6.2.1. pKa Affects Efficacy; 6.2.2. pKa Affects Pharmacokinetics; 6.2.3. pKa Affects Toxicity; 6.3. pKa Case Studies; 6.3.1. pKa and Activity Examples; 6.3.2. pKa and Pharmacokinetics Examples; 6.4. Structure Modification Strategies for pKa; Problems; References; Chapter 7: Solubility.
546			_aEnglish.
588	0		_aPrint version record.
650		4	_aPharmacy, Therapeutics, & Pharmacology.
650		4	_aHealth & Biological Sciences.
650		7	_aPharmacy, Therapeutics, & Pharmacology. _2hilcc
650		7	_aHealth & Biological Sciences. _2hilcc
700	1		_aKerns, Edward H.
758			_ihas work: _aDrug-like properties (Text) _1https://id.oclc.org/worldcat/entity/E39PCGK43gt4xT4bqrrprbkX7d _4https://id.oclc.org/worldcat/ontology/hasWork
936			_aBATCHLOAD
942			_2lcc _cBK _n0
948			_hNO HOLDINGS IN IQMCL - 1 OTHER HOLDINGS
999			_c34419 _d34419